Oncolytics Biotech Inc (NAS:ONCY)
$ 1.07 0 (0%) Market Cap: 82.02 Mil Enterprise Value: 64.91 Mil PE Ratio: 0 PB Ratio: 6.22 GF Score: 37/100

Oncolytics Biotech Inc. - Shareholder/Analyst Call Transcript

Jun 05, 2019 / 12:30PM GMT
Release Date Price: $1.8 (-4.76%)
Operator

Good morning. My name is Sherri, and I'll be your conference operator today. At this time, I would like to welcome everybody to Oncolytics Biotech conference call to discuss the codevelopment agreement with Pfizer and Merck KGaA. (Operator Instructions)

I will now turn the conference call over to your host, Michael Moore, Vice President, Investor Relations and Corporate Communications. Mr. Moore, please go ahead.

Michael Moore
Oncolytics Biotech Inc. - VP of IR & Corporate Communications

Thank you, Sherri. Good morning, ladies and gentlemen, and thank you for joining us on our call today to discuss this very important codevelopment agreement. With me on the call this morning from Oncolytics are Dr. Matt Coffey, President and Chief Executive Officer; Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development; and Kirk Look, Chief Financial Officer.

On today's call, Dr. Coffey will discuss the codevelopment agreement announced this morning between Oncolytics and pharma partners Pfizer and Merck KGaA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot